BRISBANE, Calif.--(BUSINESS WIRE)--Dec. 7, 2017--
Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company
developing treatments for life-threatening food allergies, today
announced that Chief Financial Officer Eric Bjerkholt will participate
in a fireside chat at the BMO Capital Markets 2017 Prescriptions for
Success Healthcare Conference on Thursday, December 14, 2017, in New
A live webcast of the presentation will be accessible on the Events page
under the Investor Relations section of the Aimmune website at www.aimmune.com.
A replay of the webcast will be available for at least 30 days following
About Aimmune Therapeutics
Aimmune Therapeutics, Inc., is a clinical-stage biopharmaceutical
company developing treatments for life-threatening food allergies. The
company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™)
approach is intended to achieve meaningful levels of protection by
desensitizing patients with defined, precise amounts of key allergens.
Aimmune’s first investigational biologic product using CODIT™, AR101 for
the treatment of peanut allergy, has received the FDA’s Breakthrough
Therapy Designation for the desensitization of peanut-allergic patients
4-17 years of age and is currently being evaluated in Phase 3 clinical
trials. For more information, please see www.aimmune.com.
This press release concerns a product that is under clinical
investigation and that has not yet been approved for marketing by the
U.S. Food and Drug Administration (FDA) or the European Medicines Agency
(EMA). It is currently limited to investigational use, and no
representation is made as to its safety or effectiveness for the
purposes for which it is being investigated.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171207005346/en/
Source: Aimmune Therapeutics Inc.
Aimmune Therapeutics Inc.